G.W.E. Santen

Dr. G.W.E. Santen


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GSG.W.E. Santen
G.W.E. Santen
EAEmmelien Aten
Emmelien Aten
YSYu Sun
Yu Sun
RARowida Almomani
Rowida Almomani
CGChristian Gilissen
Christian Gilissen
MKMarjolein Kriek
Marjolein Kriek

8 August 2013 in Human Mutation
Verified
Journal Article
Closed access
PDF file
GSG.W.E. Santen
G.W.E. Santen
EAEmmelien Aten
Emmelien Aten
ASAnneke T. Vulto-Van Silfhout
Anneke T. Vulto-Van Silfhout
CPCaroline Pottinger
Caroline Pottinger
BBBregje W.M. van Bon
Bregje W.M. van Bon
GYGozde Yesil
Gozde Yesil

12 March 2015 in Human Mutation
Verified
Journal Article
Closed access
PDF file
YSYu Sun
Yu Sun
CRClaudia A.L. Ruivenkamp
Claudia A.L. Ruivenkamp
MHMariëtte J.V. Hoffer
Mariëtte J.V. Hoffer
TVTerry Vrijenhoek
Terry Vrijenhoek
MKMarjolein Kriek
Marjolein Kriek
GSG.W.E. Santen
G.W.E. Santen
Although the benefits of next-generation sequencing (NGS) for the diagnosis of heterogeneous diseases such as intellectual disability (ID) are undisputed, there is little consensus on the relative merits of targeted enrichment, whole-exome sequencing (WES) or whole-genome sequencing (WGS). To answer this question, WES and WGS data from the same nine samples were compared, and WES was shown not to miss any variants identified by WGS in a gene panel including ∼500 genes linked to ID (500GP). Additionally, deeply sequenced WES data were shown to adequately cover ∼99% of the 500GP; thus, little additional benefit was to be expected from a targeted enrichment approach. To reduce costs, minimal sequencing criteria were determined by investigating the relation between sequenced reads and outcome parameters such as coverage and variant yield. Our analysis indicated that 60 million reads yielded a mean coverage of ∼60×: ∼97% of the 500GP sequences were sufficiently covered to exclude variants, whereas variant yield was ∼99.5% and false-positive and false-negative rates were controlled. Our findings indicate that WES is currently the optimal approach to ID diagnostics. This result depends on the capture kit and sequencing strategy used. The developed framework however is amenable to other sequencing approaches.

8 November 2018 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
PSPleuntje J. van der Sluijs
Pleuntje J. van der Sluijs
SJSandra Jansen
Sandra Jansen
SVSamantha A. Vergano
Samantha A. Vergano
MAMiho Adachi-Fukuda
Miho Adachi-Fukuda
YAYasemin Alanay
Yasemin Alanay
GSG.W.E. Santen
G.W.E. Santen
Purpose Pathogenic variants in ARID1B are one of the most frequent causes of intellectual disability (ID) as determined by large-scale exome sequencing studies. Most studies published thus far describe clinically diagnosed Coffin–Siris patients (ARID1B-CSS) and it is unclear whether these data are representative for patients identified through sequencing of unbiased ID cohorts (ARID1B-ID). We therefore sought to determine genotypic and phenotypic differences between ARID1B-ID and ARID1B-CSS. In parallel, we investigated the effect of different methods of phenotype reporting. Methods Clinicians entered clinical data in an extensive web-based survey. Results 79 ARID1B-CSS and 64 ARID1B-ID patients were included. CSS-associated dysmorphic features, such as thick eyebrows, long eyelashes, thick alae nasi, long and/or broad philtrum, small nails and small or absent fifth distal phalanx and hypertrichosis, were observed significantly more often (p < 0.001) in ARID1B-CSS patients. No other significant differences were identified. Conclusion There are only minor differences between ARID1B-ID and ARID1B-CSS patients. ARID1B-related disorders seem to consist of a spectrum, and patients should be managed similarly. We demonstrated that data collection methods without an explicit option to report the absence of a feature (such as most Human Phenotype Ontology-based methods) tended to underestimate gene-related features.

28 August 2014 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Closed access
PDF file
GSG.W.E. Santen
G.W.E. Santen
JCJill Clayton‐Smith
Jill Clayton‐Smith

19 May 2016 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
MFMichael D. Fountain
Michael D. Fountain
EAEmmelien Aten
Emmelien Aten
MCMegan T. Cho
Megan T. Cho
JJJane Juusola
Jane Juusola
MWMagdalena A. Walkiewicz
Magdalena A. Walkiewicz
CSChristian Schaaf
Christian Schaaf
Purpose: Truncating mutations in the maternally imprinted, paternally expressed gene MAGEL2, which is located in the Prader-Willi critical region 15q11–13, have recently been reported to cause Schaaf-Yang syndrome, a Prader-Willi-like disease that manifests as developmental delay/intellectual disability, hypotonia, feeding difficulties, and autism spectrum disorder. The causality of the reported variants in the context of the patients’ phenotypes was questioned, as MAGEL2 whole-gene deletions seem to cause little or no clinical phenotype. Methods: Here we report a total of 18 newly identified individuals with Schaaf-Yang syndrome from 14 families, including 1 family with 3 individuals found to be affected with a truncating variant of MAGEL2, 11 individuals who are clinically affected but were not tested molecularly, and a presymptomatic fetal sibling carrying the pathogenic MAGEL2 variant. Results: All cases harbor truncating mutations of MAGEL2, and nucleotides c.1990–1996 arise as a mutational hotspot, with 10 individuals and 1 fetus harboring a c.1996dupC (p.Q666fs) mutation and 2 fetuses harboring a c.1996delC (p.Q666fs) mutation. The phenotypic spectrum of Schaaf-Yang syndrome ranges from fetal akinesia to neurobehavioral disease and contractures of the small finger joints. Conclusion: This study provides strong evidence for the pathogenicity of truncating mutations of the paternal allele of MAGEL2, refines the associated clinical phenotypes, and highlights implications for genetic counseling for affected families. Genet Med 19 1, 45–52.